Toxicol Sci. 2012 Oct;129(2):411-20. Characterization of mitophagy in the 6-hydoxydopamine Parkinson’s disease model. Solesio ME1, Saez-Atienzar S, Jordán J, Galindo MF. 1Unidad de Neuropsicofarmacología Traslacional, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. Abstract In the present study, the activation of autophagy and its interaction with the mitochondrial fission machinery was investigated in an experimental model […]Take a Tour
Neuroprotective effects of TEMPOL in central and peripheral nervous system models of Parkinson’s disease.
Biochem Pharmacol. 2005 Nov 1;70(9):1371-81. Liang Q¹, Smith AD, Pan S, Tyurin VA, Kagan VE, Hastings TG, Schor NF. ¹Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA Abstract TEMPOL (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl) is a stable nitroxyl antioxidant. Previous studies have suggested that TEMPOL is protective in acute disorders thought to involve reactive oxygen species (ROS), such as […]Take a Tour
Mitochondria-targeted antioxidants for treatment of Parkinson’s disease: Preclinical and clinical outcomes.
Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease Volume 1842, Issue 8, August 2014, pp 1282–1294 Misfolded Proteins, Mitochondrial Dysfunction, and Neurodegenerative Diseases Jin H1, Kanthasamy A, Ghosh A, Anantharam V, Kalyanaraman B, Kanthasamy AG 1 Parkinson’s Disorder Research Laboratory, Iowa Center for Advanced Neurotoxicology, Department of Biomedical Sciences, Iowa State University, Ames, IA […]Take a Tour